Abeona congratulates Ultragenyx after FDA approval of FAYUVI gene therapy
Abeona Therapeutics said the FDA approval of Ultragenyx’s FAYUVI™ gene therapy is a milestone for patients with MPS IIIA and validated its own R&D and clinical development efforts.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.